Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Best Buy Co Inc (BBY) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Best Buy Co IncTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Best Buy Co Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Best Buy Co Inc trades at $82.77 (market cap $17.55B), while Ginkgo Bioworks Holdings Inc trades at $7.41 (market cap $505.73M). The key difference: Best Buy Co Inc is far larger — about 34.7× Ginkgo Bioworks Holdings Inc's market cap, and Best Buy Co Inc pays a 4.61% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

BBYDNA
Market Cap
$17.55B$505.73M
Sector
Consumer CyclicalHealth
52-Week High
$90.17$16.14
52-Week Low
$55.52$5.48
Enterprise Value
$19.93B$607.68M
Dividend Yield
4.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Best Buy Co Inc

BBY trades at $82.43, up 0.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 39.1% ROE and trades at a P/E of 15.42, below the sector average. Recent news includes leadership changes and store format tests aimed at growth.

Outlook is mixed: analyst consensus is a hold with a $84.31 price target, but risks include declining revenue and competitive pressures. Upside potential exists if new strategies boost sales, while downside is capped by solid cash flow and dividend payments.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Returns comparison

Trailing returns across standard periods

About Best Buy Co Inc

With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

Read more on BBY

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA